TNF- −308 promoter polymorphism in patients with rheumatoid arthritis

By Pawlik A.   Florczak M.   Ostanek L.   Brzosko M.   Brzosko I.   Szklarz B. Gawronska  

Scandinavian Journal of Rheumatology, Vol. 34, Iss. 1, 2005-02 ,pp. : 22-26

Informa Healthcare

Access to resources Recommend Favorite

Analysis of the levels of tumour necrosis factor (TNF), autoantibodies to TNF, and soluble TNF receptors in patients with rheumatoid arthritis

By Lopatnikova1 JA   Golikova1 EA   Shkaruba2 NS   Sizikov2 AE   Sennikov1 SV  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 6, 2013-11 ,pp. : 429-432

Informa Healthcare

Access to resources Recommend Favorite

Association between TNF-α promoter –308 A/G polymorphism and rheumatoid arthritis: a meta-analysis

By Song Gwan   Bae Sang-Cheol   Kim Jae-Hoon   Lee Young  

Rheumatology International, Vol. 34, Iss. 4, 2014-04 ,pp. : 465-471

Springer Publishing Company

Access to resources Recommend Favorite

Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

By Li Sophia   Kaur Primal   Chan Virginia   Berney Steven  

Clinical Rheumatology, Vol. 28, Iss. 7, 2009-07 ,pp. : 787-791

Springer Publishing Company

Access to resources Recommend Favorite

Treatment with anti-TNF-α antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis

By Kageyama Yasunori   Takahashi Masaaki   Torikai Eiji   Suzuki Motohiro   Ichikawa Tetsuya   Nagafusa Tetsuyuki   Koide Yukio   Nagano Akira  

Clinical Rheumatology, Vol. 26, Iss. 4, 2007-04 ,pp. : 505-509

Springer Publishing Company

Access to resources Recommend Favorite